Upcoming Meeting to Highlight New Research on Treatment Side Effects, Cancer Prevention, Drug Shortages, Health Inequities

ALEXANDRIA, Va. - Six studies exploring ways to reduce health disparities and improve the lives of patients with cancer will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Quality Care Symposium's official Press Program. Studies featured in the Press Program are among the over 400 abstracts that will be presented at the Symposium and cover a range of topics including cancer prevention, drug shortages, managing side effects of treatment, financial toxicity, and more.

The 2024 ASCO Quality Care Symposium will bring together interdisciplinary experts and pioneers in quality improvement to discuss the most important science and topics in quality care today. The Meeting will take place September 27-28 in San Francisco, California and online.

Abstract titles are now available online and the full abstracts will be publicly released on ASCO.org/qcs-abstracts on Monday, September 23, at 5:00 PM (ET) and the embargo will lift at that time.

ASCO QUALITY CARE SYMPOSIUM PRESS PROGRAM

The following research will be highlighted in press releases:

• A nationwide double-blind phase III randomized clinical trial of olanzapine vs. prochlorperazine for the treatment of refractory nausea in patients receiving moderately or highly emetogenic chemotherapy among National Cancer Institute Community Oncology Research Program practices. (Abstract 185)
• Evolution of overall survival after curative-intent lung cancer surgery in a population-based Mississippi Delta cohort.(Abstract 278)
• Radon mitigation in Native communities: A partnership between a tribal health clinic and University of Wisconsin Carbone Cancer Center. (Abstract 44)
• Prescription predicament: Unveiling the financial fallout of drug shortages. (Abstract 1)
• The role of physical activity in falls prevention among older, actively treated cancer populations. (Abstract 224)
• Financial toxicity and unmet social needs in adolescents and young adults (AYA) with cancer. (Abstract 13)

The following studies will be included in the official ASCO Tip Sheet, a brief list of additional noteworthy research that includes further context from lead study authors and ASCO Experts:  

• Molecular correlates of social adversity in breast cancer. (Abstract 48)
• Development and validation of a risk prediction model for acute care use among patients with advanced cancer on clinical trials. (Abstract 277)
• Influence of an AYA cancer program on cancer care delivery. (Abstract 4)
• Understanding health literacy's moderating role in remote monitoring for adjuvant endocrine therapy: Findings from a randomized clinical trial. (Abstract 45)
• Impact of real-world remote symptom monitoring program on hospitalizations and ICU admissions. (Abstract 377)

MEDIA RESOURCES

In-person or online-only registration is complimentary for reporters who meet ASCO's requirements for media credentials. In addition, reporters with approved media credentials can access the embargoed media materials, session livestreams, and on-demand content.

For more information on how to apply for ASCO media credentials and/or to register for the meeting, please visit the ASCO Quality Care Symposium Media Resource Center.

Please note: If you currently have approved ASCO media credentials, you must RSVP via this link if you would like to have access to the meeting livestreams and on-demand content to cover the meeting remotely.

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer's full continuum. Learn more at www.ASCO.org, and follow us on Facebook, X, LinkedIn, Instagram, and YouTube.